89-7585-85　［取扱停止］Smad3 Monoclonal Antibody 200uL　E-AB-22229

特徴

• 主な研究分野例：Cancer, Epigenetics and Nuclear Signaling, Metabolism, Signal Transduction, Stem Cells
• 背景：Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.

仕様

• 抗体タイプ：モノクローナル 抗体
• アプリケーション：IHC-p
• 交差性：Human
• 宿主：Mouse
• アイソタイプ：IgG
• 濃度：1 mg/mL
• 抗原：Synthetic Peptide of Smad3
• 緩衝液：PBS with 0.02％ sodium azide, 0.5％ BSA and 50％ glycerol, pH7.4
• 精製方法：Protein A purification
• 希釈倍率：IHC 1：100-200
• 標識：Unconjugated
• クローナリティ：Monoclonal
• メーカーマニュアルリンク：https://www.elabscience.com/viewpdf-42078-Elabscience-E-AB-22229.pdf
• サイズ：200uL
• この商品は法規制を確認しておりません。（法規制によって販売できない場合もございます）

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]